Baxdrostat is a potent aldosterone synthase (CYP11B2) inhibitor currently under clinical investigation for the potential treatment of hypertension. In pharmaceutical research and development, high-quality… Read more
Baxdrostat is a potent aldosterone synthase (CYP11B2) inhibitor currently under clinical investigation for the potential treatment of hypertension. In pharmaceutical research and development, high-quality reference standards are essential to support rigorous analytical testing and method validation. This category encompasses the active pharmaceutical ingredient, along with its specific impurities and metabolites, including the N-oxide and N-desmethyl derivatives. Additionally, stable isotope labelled compounds are available to serve as internal standards, which are critical for precise quantitative analysis in quality control assays. These materials are utilized by laboratory professionals to facilitate comprehensive impurity profiling, track degradation pathways, and ensure the structural integrity of the compound throughout synthesis and formulation development. By providing access to racemic mixtures, enantiomers, and key synthetic intermediates, this collection assists in maintaining stringent regulatory compliance during the evaluation of this novel therapeutic agent.